Skip to main content
OpenTrials
Recruiting

NCT Number: NCT05661318

AHC Ballana Heart Study

This Study is designed to assess CVD incidence, prevalence, progression and related risk factors, including genetic background. It will provide an important base for all cardiovascular research activities in our centre and help in designing future studies and guide policy.

Recruiting

Interested in participating?

Request Info

Key information

Conditions

Genetic Predisposition to Disease Disease Attributes Disease Susceptibility Pathologic Processes Pathological Conditions, Signs and Symptoms

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

About this study

Background Population-based longitudinal studies are a cornerstone in understanding current disease landscapes affecting communities and collecting reliable data to guide prevention and treatment strategies. In Egypt there is pressing need of collecting reliable data on cardiovascular disease (CVD) in defined populations.

Objectives Defining the cardiovascular phenotype, genotype as well as OMICS and risk factors for CVD in a defined population in Egypt with follow up for up to 30 years

Methods As a first step, a random representative sample of 1,200 households from the Ballana population will be created. Following inclusion, patients will be screened for their cardiovascular profile and followed up for changes in their profile and cardiovascular events continuously every year in high risk patients and every 3 years for the rest of the participants for a period of 30 years.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Residents of Ballana from the 1,200 randomly selected households
  • Participants must have a valid National ID card
  • Written informed consent

Exclusion criteria

  • Residents who are younger than 18 years

Treatment and study plan

Risk Assessment

Other

Collect clinical, laboratoary and genetics data from the participants after informed consent

Primary outcomes

  1. Cardiovascular risk assessment

    Time frame: 30 years

Study contacts

Contact information is provided by the study sponsor or research team.

Ahmed Elguindy, MD

CONTACT

[email protected]

+201001615151

Yasmine Aguib, PhD

CONTACT

[email protected]

+201092036368

Sponsors and collaborators

Lead sponsor

Magdi Yacoub Heart Foundation

Other

Registry information

Official study title

Aswan Heart Centre - Ballana Heart Study

Acronym: AHC-BHS

Important dates

Study start
2018
Primary completion
2050
Study completion
2055
First posted
Dec 22, 2022
Registry last updated
May 29, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.